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Objectives: Immune thrombocytopenia (ITP) causes increased platelet destruction and suboptimal platelet production, increasing risk of bleeding. This analysis uses a Bayesian metaregression model
to indirectly compare effectiveness of the thrombopoietin mimetics romiplostim and eltrombopag for increasing platelet counts, and contrasts the results with those of non-Bayesian approaches.
Methods: Ten databases were searched during 2010. Placebo-controlled trials of 24 weeks’ duration were included. An indirect comparison was undertaken using Bayesian metaregression, which
includes all trials in a single model. This was compared with previous analyses in which data for each intervention were combined using simple pooling, logistic regression or meta-analysis, followed by
indirect comparison of pooled values using the Bucher method.
Results: Two trials of romiplostim and one of eltrombopag were included. The indirect evidence suggests romiplostim significantly improves overall platelet response compared with eltrombopag.
Bayesian metaregression gave an odds ratio (OR) for eltrombopag versus romiplostim of 0.11 (95 percent credible interval 0.02–0.66); p values and Bayesian posterior probabilities ranged from
0.01 to 0.05 for all analyses. There was no significant difference in durable platelet response in any of the analyses, although the direction of effect favored romiplostim (OR = 0.15; 95 percent
credible interval, 0.01–1.88); p values and Bayesian posterior probabilities ranged from 0.08 to 0.40 across analyses. Results were relatively consistent between analyses.
Conclusions: Bayesian metaregression generated similar results to other indirect comparison methods, and may be considered the most robust as it incorporates all data in a single model and accounts
appropriately for parameter uncertainty.
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Immune (idiopathic) thrombocytopenia (ITP) is an autoimmune
condition characterized by increased platelet destruction and
suboptimal platelet production, resulting in low platelet counts
(thrombocytopenia) (21). Patients experience bleeding-related
symptoms ranging from minor bruising to severe gastrointesti-
nal or intracranial hemorrhage, which may be fatal. Adult ITP is
generally a chronic condition (21); incidence was estimated as
3.9 per 100,000 person-years in a recent UK study (23). Man-
agement of adult ITP includes various therapies that interfere
with platelet destruction throughmodulation of the immune sys-
tem. Newly diagnosed patients usually receive corticosteroids,
but may also require intravenous immunoglobulin (IVIg) to
address dangerously low platelet counts. Long-term use of
corticosteroids and immunoglobulins is associated with poor
safety and tolerability and high costs (21). Potential second-
line options include splenectomy or various drug treatments
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(21). Following splenectomy, approximately two-thirds of pa-
tients achieve sustained response for at least 5 years, with others
having partial or transient responses. Approximately 14 percent
do not respond, while 20 percent of responders later relapse.
Complications of splenectomy include surgical morbidity and
mortality, thrombosis, and lifelong increased risk of infection
(21). Five-year mortality estimates for ITP patients with persis-
tent low platelet counts (<30 × 109/L) range from 2.2 percent
for patients under 40 years to 47.8 percent for those over 60
years (7), with bleeding and infection contributing equally to
mortality (20;21).
The glycoprotein hormone thrombopoietin regulates
platelet production via the thrombopoietin receptor on
megakaryocytes. Recently, thrombopoietin mimetic drugs have
been introduced; these stimulate platelet production via activa-
tion of the thrombopoietin receptor. Two thrombopoietinmimet-
ics are currently approved in the US and Europe: romiplostim
and eltrombopag. Romiplostim is a peptibody (Fc-peptide fu-
sion protein) thrombopoietin mimetic, while eltrombopag is a
small-molecule thrombopoietin mimetic; both increase platelet
counts. The major goal of ITP therapy is a sustained in-
crease in platelet count that is considered safe for the indi-
vidual patient (21;22). Correspondingly, the outcomes assessed
in this analysis are platelet response rates, generally defined
as the percentage of patients achieving a platelet count above
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a certain threshold (21). The specific definitions of platelet
response in the included trials are described in the Results
section.
There are no head-to-head randomized controlled trials
(RCTs) comparing romiplostim versus eltrombopag; however,
recent trials have compared each against placebo. Indirect com-
parisons are recommended in the UK National Institute for
Health and Clinical Excellence (NICE) methods guide where
no head-to-head RCTs exist (18). An indirect comparison for
romiplostim and eltrombopag was previously conducted within
the eltrombopag Single Technology Appraisal (STA) submis-
sion to NICE (10). This analysis included two trials of romi-
plostim (one in splenectomized and one in nonsplenectomized
participants) and one trial of eltrombopag (36 percent of partic-
ipants splenectomized). The romiplostim data were pooled by
simply summing the frequencies of platelet response across the
romiplostim arms of the two trials, and similarly summing the
data across the two placebo arms. This method of pooling was
questioned within the corresponding NICE Evidence Review
Group (ERG) review of the submission, as it breaks within-
trial randomization (8). The ERG report for eltrombopag (8)
presented an alternative analysis in which the romiplostim data
were pooled using logistic regression. This method may result
in underestimated standard errors for treatment effects, as it in-
cludes a fixed treatment effect and effectively treats the results
of the two trials as arising from a single trial with a common
study effect (12).
The objectives of this analysis were to explore additional
methods for undertaking the indirect comparison of romiplostim
and eltrombopag, particularly methods allowing robust consid-
eration of parameter uncertainty, and to compare the results
with those previously presented. First, we explored alternative
methods of pooling the romiplostim data. Second, while the
above analyses pooled the data on each intervention followed
by indirect comparison of pooled values, we planned to under-
take a Bayesian metaregression analysis combining results of
all trials for both interventions within a single model. Bayesian
analysis estimates a parameter by combining two components:
the “likelihood function” or observed data model (e.g., trial
data), and the “prior distribution” based on prior assumptions
about parameters in the model. The resulting distribution is
known as the “posterior distribution.” In this way, Bayesian
analyses take account of uncertainty when estimating the value
of a parameter in the general population (19). Indirect compar-
isons preserve within-trial randomization by comparing relative
treatment effects (e.g., odds ratios, ORs) from each trial, rather
than comparing individual treatment arms from different trials
(13). The power to detect significant effects is usually lower
for an indirect comparison, resulting in larger standard errors.
In addition, it is important to account properly for heterogene-
ity between studies, so the variability of relative effects is not
underestimated. This report presents an indirect comparison of
romiplostim and eltrombopag using Bayesian metaregression,
and contrasts the results with those of previous indirect com-
parisons using non-Bayesian approaches.
METHODS
Systematic Identification of Trials
A systematic review was undertaken to identify relevant
RCTs of romiplostim and eltrombopag for ITP. The following
databases were searched in February 2010: MEDLINE, MED-
LINE in Process, EMBASE, CINAHL, Cochrane Central Reg-
ister of Controlled Trials (CENTRAL), Cochrane Database of
Systematic Reviews, NHS EED and NHS HTA, Science Cita-
tion Index, and BIOSIS Previews. Additional focused searches
were undertaken in October 2010. Abstracts of the American
Society of Hematology (ASH) and the European Hematology
Association were searched for 2007–09. The Medline search
strategy is shown in Supplementary Appendix 1, which can
be viewed online at www.journals.cambridge.org/thc2012029.
Following identification of a relevant eltrombopag trial from
conference abstracts, the main journal publication was sought
after the main literature searches.
Trials were included if they were RCTs comparing romi-
plostim or eltrombopag versus placebo for management of ITP,
had a treatment duration of at least 24 weeks, were double-
blind (patients and investigators blinded) and reported data on
platelet response. Trial quality was assessed using criteria from
the Cochrane Collaboration (6). Three trials, two of romiplostim
and one of eltrombopag, met the inclusion criteria (the same
trials were included in previous analyses reported within the
eltrombopag STA submission and ERG review).
Indirect Comparison Methods
Previous indirect comparisons of romiplostim and eltrombopag,
undertaken within the eltrombopag STA submission and ERG
review, were replicated. Further analyses were undertaken us-
ing alternative methods for pooling the romiplostim data. Fi-
nally, the indirect comparison was undertaken using a Bayesian
metaregression model which includes data from all three trials
(romiplostim and eltrombopag) in a single model.
Previous Methods of Indirect Comparison
Analysis 1: Summing of Romiplostim Data Then Bucher Indirect Comparison. The anal-
yses within the eltrombopag STA submission (10) pooled the
romiplostim data by summing frequencies of platelet response
across the romiplostim arms of the two trials, and similarly sum-
ming the data across the placebo arms of the two trials. This
method of pooling was questioned within the ERG review as
it breaks within-trial randomization (8). The method proposed
by Bucher et al. (1997) (1) was then used to indirectly com-
pare eltrombopag and romiplostim. This method is essentially a
comparison between two relative effects, and can compare two
treatments (A and C) which have not been compared directly,
but have each been compared with a common comparator (B).
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The relative treatment effect (OR) for A versus C can be esti-
mated as: indirect ORAC = ORAB / ORCB. This can be written
on a log scale as: log(ORAC) = log(ORAB) – log(ORCB). This
method assumes that the underlying treatment effect for each
comparison is fixed (12).
Analysis 2: Logistic Regression (Fixed Treatment Effects) to Pool Romiplostim Data Then
Bucher Indirect Comparison. The analyses undertaken within the ERG
review (8) again used two steps. Romiplostim data were pooled
using logistic regression; data from all trial participants were
used tomodel the relationship between platelet response and two
binary variables: treatment with romiplostim or placebo, and
splenectomy status (no interaction between these was assumed).
It was assumed that the treatment effect was fixed; that is, that
the effect of romiplostim in the general population was a fixed
value and the ORs only varied between trials due to sampling of
trial populations. The indirect comparison was then conducted
using the Bucher method (1).
Alternative Methods for Indirect Comparison
Analysis 3: Meta-analysis to Pool Romiplostim Data Then Bucher Indirect Comparison.
As an alternative to Analysis 1, we pooled the romiplostim
trial data using standardmeta-analysis. The fixed-effectMantel-
Haenszel approach was used to calculate study weights because
the placebo groups all had small event rates (this approach
does not allow random effects to be introduced) (6). A Bucher
indirect comparison was then conducted (1).
Analysis 4: Logistic Regression (Random Treatment Effects) to Pool Romiplostim Data
Then Bucher Indirect Comparison. As an alternative to Analysis 2, we
used logistic regression to combine data from the romiplostim
trials. A random effects model was used for the treatment effect,
whereby the effect of romiplostim in the general population was
assumed to follow an underlying distribution and the ORs in
each trial were assumed random samples from this distribution.
A logistic regression analysis was conducted assuming a prior
distribution for the between-trials standard deviation. A Bucher
indirect comparison was then conducted (1).
Analysis 5: Bayesian Metaregression. Bayesian metaregression anal-
yses using a logit model were conducted to indirectly
compare eltrombopag and romiplostim (detailed in Sup-
plementary Appendix 2, which can be viewed online at
www.journals.cambridge.org/thc2012029; contained therein is
Supplementary Table 1, which also can be viewed online at
www.journals.cambridge.org/thc2012029). Whereas Analyses
2 and 4 used logistic regression to pool the romiplostim data,
the Bayesian analysis used logistic regression to pool data from
all trials (romiplostim and eltrombopag), according to standard
practice (12;16;25). The model estimated probability of platelet
response per treatment group per trial, based on three parame-
ters: study effect (log-odds of response for placebo group in that
trial); treatment effect (log OR for romiplostim or eltrombopag
versus placebo); and effect of splenectomy (log OR for splenec-
tomized versus nonsplenectomized groups). The study effect
and splenectomy effect were allocated noninformative Normal
prior distributions with mean = 0 and SD = 1,000, again ac-
cording to standard practice (25). Each study effect was allo-
cated a separate parameter (16). A random effects model was
assumed for treatment effects, based on a Normal distribution.
Themodel estimated a treatment effect (logOR) for romiplostim
versus placebo and eltrombopag versus placebo. The indirect
log OR for eltrombopag versus romiplostimwas estimated from
the posterior distribution for the difference between the two
treatment effects (16). The between-trial variance for treatment
effect was assumed to be common across all trials (according
to standard practice) because there was little data from which
to estimate a separate variance for each treatment. The prior
distribution for treatment effect standard deviation (uniform
distribution between 0 and 0.6) reflected a general suggestion
from Sutton et al., so that any observed OR may vary by up to
4.6 times greater (or 0.22 times smaller) than the true OR with
equal probability (25). Analyses were conducted using Markov
chain Monte Carlo (MCMC) sampling within OpenBUGS, the
open software license equivalent of WinBUGS (OpenBUGS, v
3.0) (24).
Compared with Analysis 5, Analyses 3 and 4 are limited by
two factors. First, the likelihood function in Analysis 5 samples
from the binomial, that is, true, distribution, whereas Analyses
3 and 4 rely on a Normal approximation assumption. Such
approximations perform poorly when event rates are small, as
in the placebo groups discussed here, as the binomial likelihood
function is highly skewed. Also, Analysis 5 allows more precise
modeling of uncertainty, which is especially important when
the number of studies is small.
RESULTS
Characteristics and Quality of Included Trials
The literature search identified four RCTs of romiplostim and
four RCTs of eltrombopag. Of these, one romiplostim trial (3)
and three eltrombopag trials (2;4;26) were excluded due to short
treatment duration of 6 weeks. An additional romiplostim trial
(15)was excluded as it was an open-label trial designed to assess
requirement for splenectomy rather than platelet response; it
also differed from the included romiplostim trials on inclusion
criteria (platelet count <50 × 109/L rather than <30 × 109/L)
romiplostim starting dose (3 µg/kg rather than 1 µg/kg), and
comparator arm (standard-of-care alone rather than placebo).
Therefore, two RCTs of romiplostim (Kuter 2008a and
Kuter 2008b) (14) and one RCT of eltrombopag (Cheng 2011;
RAISE trial) (5) were considered relevant for inclusion in the in-
direct comparison (Table 1). All three were double-blind phase
III RCTs comparing either romiplostim or eltrombopag against
placebo in adults with ITP (platelet count <30 × 109/L and
failed ≥ 1 prior ITP therapy); with treatment duration ≥ 24
weeks; and reporting platelet response. Romiplostim was ad-
ministered at a starting dose of 1 µg/kg/week and eltrombopag
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Table 1. Characteristics and Quality of Included Trials
Treatment
Trial Trial design and quality duration N Treatment Comparator Concomitant therapies Population
Romiplostim
Kuter 2008a (14) (trial
20030105)
Splenectomized
• Phase III
• Randomised (stratified by concurrent ITP
medications)
• Double-blind (subjects and study site personnel)
• Allocation concealed (automated telephone
system)
• Sample size calculation; adequate power
• Intention-to-treat analysis
24 weeks 63 Romiplostim 1µg/kg/week
(adjusted to maximum 15
µg/kg). Median weekly
dose 3 µg/kg. N = 42
Placebo
N = 21
Both groups could receive
concomitant and
rescue therapies as
required
Adults with chronic ITP,
platelets < 30 ×
109/L, completed
≥ 1 prior therapy
All splenectomized
Kuter 2008b (14) (trial
20030212)
Non-splenectomized
• Phase III
• Randomised (stratified by concurrent ITP
medications)
• Double-blind (subjects and study site personnel)
• Allocation concealed (automated telephone
system)
• Sample size calculation; adequate power
• Intention-to-treat analysis
24 weeks 62 Romiplostim 1µg/kg/week
(adjusted to maximum 15
µg/kg). Median weekly
dose 2 µg/kg. N = 41
Placebo
N = 21
Both groups could receive
concomitant and
rescue therapies as
required
Adults with chronic ITP,
platelets < 30 ×
109/L, completed ≥
1 prior therapy
All non-splenectomized
Eltrombopag
RAISE trial (TRA102537)
Cheng 2011 (5);
eltrombopag STA
report (10)
36% splenectomized
• Phase III
• Randomized (stratified by splenectomy status;
concurrent ITP medications; platelet count)
• Double-blind (patients, investigators, and those
assessing data)
• Allocation concealed (automated telephone
system)
• Sample size calculation; adequate power
• Intention-to-treat analysis
26 weeks 197 Eltrombopag 50 mg/day
(adjusted to maximum 75
mg/day) N = 135
Placebo
N = 62
Both groups could receive
concomitant and
rescue therapies as
required
Adults with chronic ITP of
>6 months’ duration,
platelets < 30 ×
109/L, relapsed or
refractory to ≥ 1 prior
therapies
71/197 (36%)
splenectomized
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at 50 mg/day; doses were adjusted based on platelet count; and
patients could receive concomitant and rescue therapies as re-
quired. Platelet counts were assessed weekly in the romiplostim
RCTs (14), while for eltrombopag they were assessed weekly
for the first 6 weeks and at least once every 4 weeks there-
after (5). All three RCTs were of high quality, with adequate
randomization and allocation concealment, double-blinding,
adequate power, and baseline comparability between groups
(Tables 1 and 2). Baseline patient characteristics were simi-
lar across trials, with a few differences as follows (Table 2). For
romiplostim, oneRCTenrolled splenectomized patients and one
nonsplenectomized patients (50 percent splenectomized across
the two trials ) (14), while in the eltrombopag RCT 36 percent
of patients were splenectomized (and randomization stratified
by splenectomy status) (5). The percentage of patients receiving
concomitant ITP medication at baseline was slightly higher for
eltrombopag. The percentage of patients having received ≥ 3
prior therapies was slightly higher for romiplostim.
Platelet Response Rate Definitions
Platelet response rates were defined as a priori outcome mea-
sures in the romiplostim RCTs. For the eltrombopag RCT,
response rates were reported as post hoc analyses within the
eltrombopag STA submission (10); updated data were later
reported in the manufacturer’s response to the NICE Appraisal
Consultation Document (ACD) (11) and in the ERG com-
ment on this response (9). Definitions of overall and durable
response differed slightly for romiplostim and eltrombopag.
Overall platelet response was defined in the romiplostim tri-
als as the percentage of patients with a platelet count ≥ 50 ×
109/L on at least 4 weeks during the trial, excluding responses
within 8 weeks after rescue medications (14). For eltrombopag,
overall response was defined as the percentage of patients with
platelet count≥ 50 and≤ 400× 109/L for at least 4 consecutive
weeks, excluding those receiving rescue medication during the
assessment following a platelet response (11). Durable platelet
response was defined for romiplostim as the percentage of pa-
tients with platelet count ≥ 50 × 109/L on at least 6 of the last
8 weeks of treatment, with no rescue medications at any time
during the trial (14). For eltrombopag, durable response was
defined as the percentage of patients with platelet count ≥ 50
and≤ 400× 109/L on at least 6 of the last 8 weeks of treatment,
excluding subjects who received rescue medication (10).
Platelet Response Rates With Romiplostim and Eltrombopag
Overall and durable platelet response rates for the three trials are
shown in Table 3.Overall platelet response rates for romiplostim
were 33/42 (79 percent) for splenectomized patients (0/21; 0
percent for placebo) and 36/41 (88 percent) for nonsplenec-
tomized patients (3/21; 14 percent for placebo) (14). Overall
platelet response rates for eltrombopag were 26/50 (52 percent)
for splenectomized patients (2/21; 10 percent for placebo) and
51/85 (60 percent) for nonsplenectomized patients (5/41; 12
percent for placebo) (5;9–11).
Durable platelet response rates for romiplostim were 16/42
(38 percent) for splenectomized patients (0/21; 0 percent for
placebo) and 25/41 (61 percent) for nonsplenectomized pa-
tients (1/21; 5 percent for placebo) (14). Durable platelet re-
sponse rates for eltrombopag were 19/50 (38 percent) for
splenectomized patients (1/21; 5 percent for placebo) and 38/85
(45 percent) for nonsplenectomized patients (3/41; 7 percent for
placebo) (5;9–11).
Results of Indirect Comparison
The results of the indirect comparison using various methods
are summarized in Table 4. In terms of overall platelet response,
Bayesian metaregression (Analysis 5) gave an OR for eltrom-
bopag versus romiplostim of 0.11 (95 percent credible inter-
val 0.02 to 0.66). Results were consistent across analyses, all
of which gave indirect ORs ranging from 0.10 to 0.16). The
p values for non-Bayesian analyses, and Bayesian posterior
probabilities that the indirect OR did not favor romiplostim,
ranged from 0.01 to 0.05 across all analyses of overall re-
sponse. The probability density functions for the posterior dis-
tribution of the log indirect odds ratios for platelet response are
shown in Supplementary Figure 1, which can be viewed on-
line at www.journals.cambridge.org/thc2012029. The indirect
evidence suggests romiplostim significantly improves overall
platelet response rates compared with eltrombopag.
In terms of durable platelet response, the Bayesian metare-
gression analyses gave an OR of 0.15 (95 percent credible in-
terval 0.01 to 1.88). Results were relatively consistent across
analyses, with ORs ranging from 0.13 to 0.36. The lower event
rates for the durable response outcome corresponded to wider
confidence (and credible) intervals and a lack of a significant
difference between groups. P values for non-Bayesian analyses,
and Bayesian posterior probabilities that the indirect OR did
not favor romiplostim, ranged from 0.08 to 0.40 for all anal-
yses of durable response. There was no significant difference
in durable platelet response in any analysis, although the di-
rection of effect favored romiplostim. Regarding heterogeneity
between trials, the fixed-effect analyses (Analyses 2 and 3) both
gave I-squared values of 0 for both overall and durable platelet
response.
DISCUSSION
Comparison of Results of Indirect Comparison Using Different Approaches
The Bayesian metaregression results were consistent with the
non-Bayesian approaches to indirect comparison. All analyses
suggested romiplostim significantly improves overall platelet
response rates compared with eltrombopag, while all analyses
of durable platelet response favored romiplostim but were not
significant. This difference between outcomes was robust to
changes in analysismethod. Increases in platelet count represent
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Table 2. Baseline Patient Characteristics
Age (median, Platelet count Concomitant Duration of ITP, years Bleeding symptoms
Trial Trial arm range) Female Splenectomized (median) ITP medication (median, range) Prior ITP therapies at baseline
Romiplostim
Kuter 2008a (14) (trial
20030105)
Romiplostim (N = 42) 51 (27–88) 27 (64%) 42 (100%) 14 × 109/L 12 (29%) 7.8 (0.6 - 44.8) ≥ 3 therapies: 39 (93%) 78%∗
Splenectomized Placebo (N = 21) 56 (26–72) 11 (52%) 21 (100%) 15 × 109/L 6 (29%) 8.5 (1.1 - 31.4) ≥ 3 therapies: 20 (95%)
Kuter 2008b (14) (trial
20030212)
Romiplostim (N = 41) 52 (21–80) 27 (66%) 0 (0%) 19 × 109/L 11 (27%) 2.2 (0.1 – 31.6) ≥ 3 therapies: 15 (37%) 79%∗
Non-splenectomized Placebo (N = 21) 46 (23–88) 16 (76%) 0 (0%) 19 × 109/L 10 (48%) 1.6 (0.1 – 16.2) ≥ 3 therapies: 5 (24%)
All patients from two trials Romiplostim (N = 83) 52 (21–88) 54 (65%) 42 (51%) 16 × 109/L 23 (28%) Not reported ≥ 3 therapies: 54 (65%) 78%∗
Placebo (N = 42) 52 (23–88) 27 (64%) 21 (50%) 18 × 109/L 16 (38%) Not reported ≥ 3 therapies: 25 (60%)
Eltrombopag
RAISE trial (TRA102537)
Cheng 2011 (5);
eltrombopag STA report
(10)
36% splenectomized
Eltrombopag (N = 135) 47 (18–85) 93 (69%) 50 (37%) 16 × 109/L 63 (47%) Not reported ≥ 2 therapies: 105 (78%)
≥ 3 therapies: 75 (56%)
≥ 4 therapies: 51 (38%)
≥ 5 therapies: 35 (26%)
73%
Placebo (N = 62) 53 (18–77) 43 (69%) 21 (34%) 16 × 109/L 31 (50%) Not reported ≥ 2 therapies: 50 (81%)
≥ 3 therapies: 32 (52%)
≥ 4 therapies: 20 (32%)
≥ 5 therapies: 11 (18%)
77%
∗ Amgen data on file (bleeding at baseline for romiplostim).
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Table 3. Overall and Durable Platelet Response Rates for Romiplostim and Eltrombopag
Eltrombopag (1 trial) (5;10;11) Eltrombopag Placebo Romiplostim (2 trials) (14) Romiplostim Placebo
Overall response Overall response
Splenectomy 26 / 50 (52%) 2 / 21 (10%) Splenectomy (Kuter 2008a (14)) 33 / 42 (79%) 0 / 21 (0%)
No splenectomy 51 / 85 (60%) 5 / 41 (12%) No splenectomy (Kuter 2008b (14)) 36 / 41 (88%) 3 / 21 (14%)
All patients (single trial; Cheng 2011 (5)) 77 / 135 (57%) 7 / 62 (11%) All patients (across 2 trials) 69 / 83 (83%) 3 / 42 (7%)
Durable response Durable response
Splenectomy 19 / 50 (38%) 1 / 21 (5%) Splenectomy (Kuter 2008a (14)) 16 / 42 (38%) 0 / 21 (0%)
No splenectomy 38 / 85 (45%) 3 / 41 (7%) No splenectomy (Kuter 2008b (14)) 25 / 41 (61%) 1 / 21 (5%)
All patients (single trial; Cheng 2011 (5)) 57 / 135 (42%) 4 / 62 (6%) All patients (across 2 trials) 41 / 83 (49%) 1 / 42 (2%)
Note. Eltrombopag data are based on a single RCT (RAISE; Cheng 2011) (5) and patients are subgrouped according to splenectomy status. Eltrombopag data were initially reported as
post-hoc analyses within the eltrombopag STA submission to NICE (10) (p80–82); updated data were later reported in the manufacturer’s response to the NICE Appraisal Consultation
Document (ACD) (11) (p7–9) and in the ERG comment on this response (9) (p4). Romiplostim data are based on two RCTs, one in splenectomized patients and one in non-
splenectomized patients (Kuter et al 2008) (14). Definitions of overall and durable platelet response differ slightly for romiplostim and eltrombopag and are described in the main text.
decreased risk of bleeding in ITP patients, with treatment rarely
indicated in patients with counts above 50 × 109/L (21).
Comparability of Included Trials
Indirect comparisons allow comparison of two or more inter-
ventions where no head-to-head trials exist, and are consistent
with the NICE Guide to the Methods of Technology Appraisal
(18). A limitation is that included trials may differ in patient
population and trial design. Regarding patient population, the
romiplostim and eltrombopag trials were reasonably similar for
age, gender, baseline platelet count and bleeding symptoms.
Differences included percentage of splenectomized patients (50
percent across romiplostim trials, 36 percent for eltrombopag);
percentage receiving concomitant ITP medication at baseline
(slightly higher for eltrombopag); and percentage having re-
ceived ≥ 3 prior therapies (slightly higher for romiplostim).
Included trials were similar in design, with treatment duration
≥ 24 weeks. Overall and durable platelet response were pre-
specified outcomes for romiplostim, but were post hoc analy-
ses with slightly different definitions for eltrombopag. Platelet
counts were assessed weekly for romiplostim, while for eltrom-
bopag they were assessed weekly for 6 weeks then≥ once every
4 weeks. In summary, the included trials appeared sufficiently
similar, with the slight differences not clearly favoring either
treatment.
Consistency and Appropriateness of Methods
The analyses varied regarding assumptions about uncertainty in
treatment effects of romiplostim and eltrombopag. Results of
the different analyses were reasonably consistent. The appro-
priateness of each method in this case is discussed below.
Analyses Involving Pooling Romiplostim Data Followed by Bucher Indirect
Comparison
Four analyses used various methods to pool the romiplostim
data, followed by indirect comparison using the Bucher method
(1). The analysis within the eltrombopag STA submission
(Analysis 1) (10) pooled the romiplostim data by summing
platelet response frequencies across the romiplostim arms of the
two trials, and similarly summing the data across the twoplacebo
arms. This method of pooling was questioned by the ERG as it
breaks within-trial randomization (8). In contrast, our Analysis
3 usedmeta-analysis to pool the romiplostim data; this approach
does not break randomization and accounts for romiplostim data
coming from two separate trials. Results of Analyses 1 and 3
were similar for overall response. For durable response, results
were again similar, though Analysis 3 (meta-analysis) gave a
slightly lower OR for romiplostim versus placebo and there-
fore slightly higher OR for eltrombopag versus romiplostim,
possibly due to small event rates in the placebo arms of the
romiplostim trials and the 0.5 correction for values of zero.
TheERG report for eltrombopag (8) pooled the romiplostim
data using logistic regression (Analysis 2). This method may re-
sult in underestimated standard errors for treatment effects, as it
includes a fixed treatment effect and effectively treats the results
as arising from a single trial with a common study effect (12).
Our Analysis 4 was similar to the ERG analysis, using logistic
regression to combine the romiplostim data; however, we used
a random effects model for treatment effect, providing more
robust consideration of uncertainty. It is worth noting that the
logistic regression approach (Analysis 4) is based on a binomial
likelihood, whereas theMantel-Haenszel meta-analysis (Analy-
sis 3) assumes a Normal approximation. All four methods used
the Bucher method of indirect comparison, and gave relatively
consistent results (12).
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Table 4. Indirect Comparison of Eltrombopag and Romiplostim
Indirect OR eltrombopag p value or probability
OR eltrombopag vs. OR romiplostim vs. vs. romiplostim SE of log indirect OR does not
Analysis method placebo (95% CI) placebo (95% CI) (95% CI) indirect OR favor romiplostima
Overall platelet response
Previous analyses in STA submission and ERG report
Analysis 1 (eltrombopag STA): Summing of romiplostim data across trial arms then
Bucher indirect comparison
10.4 (4.4, 24.6) 64.1 (17.3, 236.8) 0.16 (0.03, 0.78) 0.798 .02
Analysis 2 (ERG report): Pooling of romiplostim data via logistic regression (fixed
treatment effects) then Bucher indirect comparison
10.4 (4.4, 24.6) 77.7 (19.5, 309.9) 0.13 (0.03, 0.68) 0.830 .02
Alternative methods for indirect comparison
Analysis 3: Meta-analysis of romiplostim data (Mantel-Haenszel weighting) then
Bucher indirect comparison
10.4 (4.4, 24.6) 68.4 (12.8, 365.6) 0.15 (0.02, 1.00) 0.961 .05
Analysis 4: Pooling of romiplostim data via logistic regression (random treatment
effects) then Bucher indirect comparison∗
10.4 (4.4, 24.6) 105.8 (24.6, 598.8) 0.10 (0.02, 0.57) 0.899 .01
Analysis 5: Bayesian metaregression of romiplostim and eltrombopag data (random
treatment effects)∗
11.6 (4.4, 33.8) 106.1 (25.0, 593.5) 0.11 (0.02, 0.66) 0.957 .01
Durable platelet response
Previous analyses in STA submission and ERG report
Analysis 1 (eltrombopag STA): Summing of romiplostim data across trial arms then
Bucher indirect comparison
10.6 (3.6, 30.9) 40.0 (5.3, 304.7) 0.26 (0.03, 2.62) 1.171 .26
Analysis 2 (ERG report): Pooling of romiplostim data via logistic regression (fixed
treatment effects) then Bucher indirect comparison
10.6 (3.6, 30.9) 45.0 (5.8, 348.4) 0.24 (0.02, 2.37) 1.178 .22
Alternative methods for indirect comparison
Analysis 3: Meta-analysis of romiplostim data (Mantel-Haenszel weighting) then
Bucher indirect comparison
10.6 (3.6, 30.9) 29.3 (3.6, 236.9) 0.36 (0.03, 3.79) 1.198 .40
Analysis 4: Pooling of romiplostim data via logistic regression (random treatment
effects) then Bucher indirect comparison∗
10.6 (3.6, 30.9) 84.2 (10.5, 2000.2) 0.13 (0.01, 2.09) 1.433 .15
Analysis 5: Bayesian metaregression of romiplostim and eltrombopag data (random
treatment effects)∗
12.5 (4.0, 47.8) 84.3 (10.3, 2036.5) 0.15 (0.01, 1.88) 1.499 .08
a The p value (non-Bayesian analyses) or probability indirect OR does not favor romiplostim (Bayesian analyses in WinBUGS, marked∗).
ERG, Evidence Review Group; CI, confidence interval (for non-Bayesian analyses) or credible interval (Bayesian analyses inWinBUGS,marked∗); OR, odds ratio; SE, standard error; STA, single technology assessment.
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Indirect comparison of romiplostim and eltrombopag
Bayesian Metaregression
Whereas Analyses 2 and 4 used logistic regression to pool the
romiplostim data only, the Bayesian indirect comparison (Anal-
ysis 5) used logistic regression to pool data from all three trials
(romiplostim and eltrombopag). The Bayesian indirect com-
parison may perhaps be considered the most robust analysis
described here, as it follows current best practice for indirect
comparisons (16), incorporating all trial data in a single model
and accounting appropriately for parameter uncertainty. Results
of this analysis were consistent with the other analyses.
CONCLUSIONS
The Bayesian metaregression for overall platelet response gave
an OR for eltrombopag versus romiplostim of 0.11 (95 percent
credible interval 0.02 to 0.66). Results were consistent across
the different analyses, all of which gave indirect OR estimates
ranging from 0.10 to 0.16, while p values and Bayesian poste-
rior probabilities ranged from 0.01 to 0.05 for all analyses of
overall response. The indirect evidence suggests romiplostim
significantly improves overall platelet response rates compared
with eltrombopag.
The Bayesian metaregression for durable platelet response
gave an OR of 0.15 (95 percent credible interval 0.01 to 1.88).
Results were again relatively consistent across analyses, with
ORs ranging from 0.13 to 0.36 and p values and Bayesian
posterior probabilities ranging from 0.08 to 0.40. The indirect
evidence does not suggest romiplostim significantly improves
durable platelet response compared with eltrombopag, though
ORs favored romiplostim.
The analyses presented here, first, explored different meth-
ods for combining data from the two romiplostim trials, and,
second, reported a Bayesian metaregression which included
data from all three trials (romiplostim and eltrombopag) in a
single model. Results of the different analyses were consistent
for both overall and durable platelet response. The Bayesian
metaregression approach generated similar results to other in-
direct comparison methods, and may be considered the most
robust of the analyses described here, as it incorporates all trial
data in a single model and accounts appropriately for parameter
uncertainty.
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